You are here: Industry Insights > Sanofi

News List

After setback, Sanofi-GSK reports success in COVID-19 vaccine expresspharma
May 18, 2021
The drugmakers said they plan to begin late-stage trials and production in the coming weeks and hope to win regulatory approval for the vaccine before the end of 2021.
Sanofi, GSK’s COVID-19 vaccine achieves positive Phase II results pharmatimes
May 17, 2021
Sanofi and GlaxoSmithKline (GSK) have reported that their COVID-19 vaccine generates strong immune responses across all adult age groups.
Sanofi to manufacture Moderna’s Covid-19 vaccine in the US pharmaceutical-technology
April 28, 2021
Sanofi has entered an agreement to manufacture up to 200 million doses of Moderna’s Covid-19 vaccine in the US.
Positive topline results for nirsevimab in RSV pharmatimes
April 27, 2021
Sanofi and AstraZeneca’s (AZ) monoclonal antibody (mAb) nirsevimab reached its primary endpoint in a Phase III trial, demonstrating protection against respiratory syncytial virus disease (RSV) in healthy infants.
Sanofi and C4X Discovery enter licensing deal worth up to €414m pharmaceutical-technology
April 13, 2021
Sanofi and drug discovery company C4X Discovery (C4XD) have entered an exclusive worldwide licensing agreement worth up to €414m for C4XD’s oral pre-clinical IL-17A inhibitor programme.
Sanofi Acquires Tidal Therapeutics contractpharma
April 13, 2021
Sanofi acquired Tidal Therapeutics, a preclinical stage biotech company with a novel mRNA-platform for reprogramming of immune cells, for $160 million upfront and up to $310 million in milestones.
Sanofi Invests in Cutting Edge Vax Production Site in Singapore contractpharma
April 13, 2021
The factory will house several fully digitalized modules that allow production of three to four vaccines simultaneously.
Sanofi to Build New $700M Flu Vaccine Facility in Canada contractpharma
April 06, 2021
Sanofi has unveiled an investment of more than €600 million (~$707mn) in a new vaccine manufacturing facility at its existing site in Toronto, Canada.
FDA green light for Sarclisa combo in multiple myeloma pharmatimes
April 01, 2021
French pharma company Sanofi has received US Food and Drug Administration (FDA) approval for its CD38 inhibitor Sarclisa in combination with carfilzomib and dexamethasone (Kd) for the treatment of advanced multiple myeloma.
Sanofi to sell anti-inflammatory drug portfolio to Fidia Farmaceutici pharmaceutical-technology
March 25, 2021
Sanofi has concluded an agreement to sell its anti-inflammatory drugs portfolio to Italian company Fidia Farmaceutici to streamline established products.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 43 44 Next page